Mentioned On
Episode Mentions
Bloomberg Intelligence · Jul 16, 2026
Lilly Strikes $3.8 Billion Deal for Psychedelic Drugmaker
“Psychedelic drugmaker being acquired by Eli Lilly for treatment-resistant depression and anxiety disorders”
Psychedelic Drug Development and RegulationEli Lilly M&A Strategy and Contingent Value RightsPCSK9 Inhibitors and Cholesterol Management
View Analysis